- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04241367
Verification of Predictive Biomarkers for Pancreatic Cancer Treatment Using Multicenter Liquid Biopsy
September 27, 2022 updated by: Sang Myung Woo, National Cancer Center, Korea
This study is for verification of predictive biomarkers for pancreatic cancer treatment using multi-center liquid biopsy.
Study Overview
Status
Active, not recruiting
Conditions
Detailed Description
Clinical applicability of KRAS mutations using circulating-tumor DNA in pancreatic cancer patients.
- Quantification and monitoring of KRAS mutations Using droplet digital PCR in ctDNA extracted from collected patient samples.
- Correlation analysis of KRAS mutation results with clinical data.
Discovery of biomarkers for predicting pancreatic cancer prognosis through ctDNA panel.
- Gene panel composition for pancreatic cancer therapeutic target determination and monitoring.
- A panel was performed using gDNA and ctDNA of tumor tissue collected from pancreatic cancer patients.
- Comparative analysis of panel results and quantitative KRAS mutations and evaluation of clinical applicability.
Study Type
Observational
Enrollment (Actual)
420
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Gyeonggi-do
-
Goyang-si, Gyeonggi-do, Korea, Republic of, 410-769
- NATIONAL CANCER CENTER 323, Ilsan-ro, Ilsandong-gu,
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Inpatient or outpatient
Description
Inclusion Criteria:
- Patients with pathologically confirmed pancreatic adenocarcinoma.
Exclusion Criteria:
- Patients disagree with the study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical applicability of KRAS mutations
Time Frame: Locally advanced and Resectable patients: Pre Treatment, 1,2,3,6,9,12,15,18,21,24months/ Metastatic patients: Pre Treatment, 1,2,4,6,8,10,12,14,16,18,20,22,24 months
|
Clinical applicability of KRAS mutations using circulating-tumor DNA in pancreatic cancer patients.
|
Locally advanced and Resectable patients: Pre Treatment, 1,2,3,6,9,12,15,18,21,24months/ Metastatic patients: Pre Treatment, 1,2,4,6,8,10,12,14,16,18,20,22,24 months
|
Discovery of biomarkers through ctDNA panel
Time Frame: Locally advanced and Resectable patients: Pre Treatment, 1,2,3,6,9,12,15,18,21,24months/ Metastatic patients: Pre Treatment, 1,2,4,6,8,10,12,14,16,18,20,22,24 months
|
Discovery of biomarkers for predicting pancreatic cancer prognosis through ctDNA panel.
|
Locally advanced and Resectable patients: Pre Treatment, 1,2,3,6,9,12,15,18,21,24months/ Metastatic patients: Pre Treatment, 1,2,4,6,8,10,12,14,16,18,20,22,24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Sangmyung Woo, MD, National Cancer Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 28, 2019
Primary Completion (Actual)
June 3, 2021
Study Completion (Anticipated)
December 31, 2025
Study Registration Dates
First Submitted
January 22, 2020
First Submitted That Met QC Criteria
January 22, 2020
First Posted (Actual)
January 27, 2020
Study Record Updates
Last Update Posted (Actual)
September 29, 2022
Last Update Submitted That Met QC Criteria
September 27, 2022
Last Verified
September 1, 2022
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NCC2019-0027
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreas Adenocarcinoma
-
The Cooper Health SystemTerminatedPancreatic Cancer | Pancreatic Adenocarcinoma | Pancreas Adenocarcinoma | Pancreas Cancer | Adenocarcinoma of the PancreasUnited States
-
The Cooper Health SystemUnknownPancreatic Cancer | Pancreatic Adenocarcinoma | Pancreas Adenocarcinoma | Pancreas Cancer | Adenocarcinoma of the PancreasUnited States
-
Samyang Biopharmaceuticals CorporationUnknownMetastatic Adenocarcinoma of the Pancreas | Recurrent Adenocarcinoma of the PancreasKorea, Republic of
-
Prof. Dr. med. Dres. h.c. Jan Schmidt, MMERecruitingPancreatic Neoplasms | Pancreatic Cancer | Pancreatic Adenocarcinoma | Pancreas Adenocarcinoma | Pancreas Cancer | Pancreas NeoplasmSwitzerland
-
Umeå UniversityKarolinska University Hospital; Sahlgrenska University Hospital, Sweden; University... and other collaboratorsRecruitingQuality of Life | Surgery | Pancreas Adenocarcinoma | Chemotherapy Effect | Pancreas Cancer | Pancreas Neoplasm | Pancreas Disease | Locally Advanced Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic AdenocarcinomaSweden
-
Washington University School of MedicineCompletedAdenocarcinoma PancreasUnited States
-
Medical College of WisconsinBarbara Ann Karmanos Cancer Institute; Cornerstone PharmaceuticalsRecruitingPancreas AdenocarcinomaUnited States
-
Capital Health System, IncRecruitingPancreas AdenocarcinomaUnited States
-
NovoCure Ltd.Active, not recruitingPancreas AdenocarcinomaUnited States, China, Belgium, Czechia, Korea, Republic of, Spain, Hong Kong, France, Australia, Italy, Hungary, Germany, Croatia, Canada, Mexico, Israel, Austria, Switzerland, Brazil, Poland
-
Centre Leon BerardActive, not recruitingPancreas AdenocarcinomaFrance